74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
Veracyte Inc
Open
SectorHealthcare
32.95 5.71
Overview
Share price change
24h
Min
31.06
Max
32.86
Income | 30M 49M |
|---|---|
Sales | 8.8M 141M |
P/E Sector Avg | 41.281 67.147 |
Profit margin | 34.967 |
Employees | 755 |
EBITDA | 22M 46M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +35.31% upside |
Next Earnings | 5 May 2026 |
|---|
Market Cap | -125M 2.7B |
|---|---|
Previous open | 27.24 |
Previous close | 32.95 |
News Sentiment
By Acuity
13%
87%
23 / 348 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Veracyte Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Veracyte Inc Forecast
Price Target
By TipRanks
35.31% upside
12 Months Forecast
Average 43 USD 35.31%
High 48 USD
Low 37 USD
Based on 7 Wall Street analysts offering 12 month price targets forVeracyte Inc - Dist in the last 3 months.
Sentiment
By Acuity
23 / 348 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Live chat